[Histonet] SISH - Ventana

[Bowlay, Greg]

Hi Gudrun,
 
We have been trialling HER2/Ch17 SISH on a Ventana Benchmark and it works very well!! We are very impressed by the contrast between signal and counterstain, particularly in the polysomy amd low amp cases. Another advantage is that the tissue architecture is maintained greatly, and also inclusion of control tissue on same slide. At around six hours for the complete run it increases our TAT's and volume.
 
We are looking at Extended CC2 and four minutes ISH protease 3 for our tissue - which preserves tissue integrity compared to the technique we currently use for CISH (Zymed).
 
We recommend it highly!!!
 
Regards
 
Greg Bowlay
Scientist
Anatomical Pathology
Mater Health Services
South Brisbane Q 4101
Greg.Bowlay <@t> mater.org.au
PH: +61 7 3840 8586
FAX: +61 7 3840 8338
 
"Far better it is to dare mighty things to win glorious triumphs even though chequered by failure, than to rank with those poor spirits who neither enjoy nor suffer much because they live in the grey twilight that knows neither victory nor defeat." Theodore Roosevelt
 

________________________________

From: histonet-bounces <@t> lists.utsouthwestern.edu on behalf of Gudrun Lang
Sent: Fri 29/6/07 1:40 AM
To: histonet <@t> lists.utsouthwestern.edu
Subject: [Histonet] SISH - Ventana



I would be interested in people's experience with the SISH-test on the
Ventana-benchmark.

SISH = Silver in situ hybridisierung for detecting Her2neu-gene copies.

The principle is metallography, where the bound HRP catalyses the reduction
of Silveracetat. This results in black dots, that can be detected with a
light microscope.



Thanks in advance



Gudrun Lang






This e-mail, together with any attachments, is confidential and intended for the named recipient(s) only. If you are not the intended recipient or have received this message in error, you are asked to immediately notify the sender and delete this message and any copies of this message from your computer system network and destroy any printed copies of this email. Any form of unauthorised disclosure, modification, distribution, publication or use of this e-mail message is prohibited.